Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01647321
Other study ID # NA_00069253
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2012
Est. completion date October 2019

Study information

Verified date March 2020
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Secondary progressive multiple sclerosis (SPMS) is a subtype of multiple sclerosis (MS) for which there are no existing therapies that alter the disease course. This research will utilize cutting edge functional electrical stimulation (FES) cycling technology with the goal of improving walking in individuals with SPMS. The investigators hypothesize that FES cycling will improve walking in subjects with SPMS.


Description:

Individuals with secondary progressive multiple sclerosis (SPMS) experience significant impairments in ambulation leading to use of canes, walkers, and ultimately wheelchairs. Treatment attempts for progressive MS have been disappointing. No therapeutic intervention has been shown to modulate disability in patients with SPMS. FES cycling has been shown to have multiple primary medical benefits including: increased muscle mass, improvements in bone density, enhanced cardiovascular function, improved bowel function, decreased spasticity and reductions in bladder infection rate. More importantly FES may modulate the inflammatory central nervous system (CNS) environment in progressive MS. The investigators are proposing a novel, and easy to implement intervention strategy of FES cycling to help improve gait function in individuals with SPMS. A successful outcome on a larger SPMS population would have significant impact towards changing MS clinical care. FES is easily transferable to clinical practice and could potentially ameliorate other complications associated with SPMS such as spasticity, mood and fatigue reducing the burden of health care cost. In addition, the investigators will gain a better understanding of the mechanisms underlying these changes that could be used to design new therapeutic strategies.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date October 2019
Est. primary completion date October 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 68 Years
Eligibility Inclusion Criteria:

- clinical diagnosis of secondary progressive multiple sclerosis

- males and females between the ages of 18 and 65 years

- Expanded disability status scale score between 5.0 and 7.0

- Able to consent to participate in study and are willing to undergo a lumbar puncture and blood draws

- If on on Ampyra or anti-spasticity agent, must be on stable dose for 1 month prior to screening

- No functional electrical stimulation use within 4 weeks

- Participants must be medically stable with no recent (1 month or less) inpatient admission for acute medical or surgical issues

Exclusion Criteria:

- Uncontrolled hypertension or other significant cardiovascular disease as determined by investigator

- History of epileptic seizures

- Subjects who have a pacemaker

- Relapse within thirty days prior to screening visit

- Pregnancy

- Subjects having a Stage 2 or greater sacral decubitus ulcer

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Active cycling
The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
Passive cycling
The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.

Locations

Country Name City State
United States Johns Hopkins / Kennedy Krieger Institute Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in timed 25 foot walk from baseline to end of training Here we will assess whether a subjects walking speed is improved following active cycling with functional electrical stimulation. Our prediction is that individuals will improve in their walking function following seated active cycling with functional electrical stimulation. Participants are assessed at baseline (visit 1), one-month (visit 2), two-months (visit 3), three-months (visit 4), end of study (visit 5)
See also
  Status Clinical Trial Phase
Completed NCT04239664 - Acceptance Based Telephone Support When Transitioning to SPMS N/A
Active, not recruiting NCT04411641 - Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) Phase 3
Completed NCT02549703 - Mitochondrial Dysfunction and Disease Progression
Terminated NCT01416181 - A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Phase 3
Withdrawn NCT01181089 - Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) Phase 1/Phase 2
Active, not recruiting NCT03471338 - Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme N/A
Withdrawn NCT05029609 - Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS Phase 1
Completed NCT02228213 - Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis Phase 2
Terminated NCT02296346 - Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis N/A
Completed NCT00559702 - Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) Phase 1
Terminated NCT03283826 - Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Phase 1/Phase 2
Completed NCT02253264 - A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Phase 1
Completed NCT01737372 - A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis N/A
Completed NCT00257855 - A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Phase 2
Recruiting NCT06292923 - A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients Phase 2
Active, not recruiting NCT01228396 - AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Phase 2
Completed NCT03896217 - Simvastatin in Secondary Progressive Multiple Sclerosis Phase 2
Completed NCT02495766 - Autologous Mesenchymal Stromal Cells for Multiple Sclerosis Phase 1/Phase 2
Completed NCT00813969 - Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS Phase 1
Completed NCT01077466 - Natalizumab Treatment of Progressive Multiple Sclerosis Phase 2